CompletedNot Applicable

Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis

China300 participantsStarted 2020-01-01

Plain-language summary

This is a clinical retrospective study that will collect and analyze clinical data from all patients treated with fumeitinib mesylate in the Oncology Department of Tiantan Hospital between January 1, 2020 and May 31, 2025. The data collection will include general demographic characteristics (gender, age, family history, smoking history, etc.), clinicopathological features, NGS test reports, fumeitinib initiation time and dosage, concomitant medications, local treatments (surgery, radiotherapy, etc.), and baseline and follow-up imaging examinations related to efficacy and safety. The study will conduct: 1) clinical data analysis; and 2) exploration of resistance-related clinical characteristics and influencing factors.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically or cytologically confirmed stage IIIb-IVb NSCLC or postoperative recurrent NSCLC;
✓. Positive EGFR test result, which can be determined by methods such as RT-PCR/FISH/IHC/NGS from hospital laboratories or testing institutions;
✓. Patients aged ≥18 years;
✓. Patients have clinically received Firmonertinib treatment, with recorded objective efficacy evaluation and adverse reactions;
✓. Sign the Beijing Tiantan Hospital broad informed consent form.

What they're measuring

iPFS

Timeframe: From first dose until the event of interest, assessed between January 1, 2020 and May 30, 2025

Trial details

NCT IDNCT07239102

SponsorBeijing Tiantan Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-05-01

View on ClinicalTrials.gov More EGFR Positive Non-small Cell Lung Cancer trials